SCHEMBL3320532

SCHEMBL3320532

CCOC(=O)c1nc(C(F)(F)F)sc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 2/20 0.51
▸ ALDH1A1 P00352 7/20 0.48
▸ HPGD P15428 5/20 0.48
▸ GRM6 O15303 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ NPSR1 Q6W5P4 3/20 0.48
▸ CDC7 O00311 2/20 0.48
▸ DBF4 Q9UBU7 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ DHODH Q02127 1/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ TARBP2 Q15633 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ NPC1 O15118 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ RARA P10276 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14691461 0.89 TRPM8 (0.51) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL3317668 0.82 ALDH1A1 (0.53) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL22459755 0.81 KDM4E (0.40) TRPM8ALDH1A1HPGDMAPTNPSR1
SCHEMBL20785682 0.81 TRPM8 (0.63) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL13398515 0.81 ALDH1A1 (0.52) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL13398662 0.81 KDM4E (0.46) ALDH1A1HPGDMAPTGAAHSD17B10
SCHEMBL3317487 0.81 TRPM8 (0.49) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL3321548 0.80 GRM6 (0.58) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL3317624 0.80 ALDH1A1 (0.72) TRPM8ALDH1A1HPGDGRM6MAPT
SCHEMBL13398727 0.80 ALDH1A1 (0.48) TRPM8ALDH1A1HPGDGRM6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 — — US disclosed
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 — — US disclosed
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 — — US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 — — US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 — — US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 — — US disclosed
EP-2119716-A1 AZA-BRIDGED-RING COMPOUND Astellas Pharma Inc. (JP) 2009-11-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND CHRM3, CHRM1, CHRM2 TRPM8 99/4885ALDH1A1 2006/4885HPGD 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback